首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >98%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LGALS2 |
| Uniprot No | P17931 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-250aa |
| 氨基酸序列 | ADNFSLHDAL SGSGNPNPQG WPGAWGNQPA GAGGYPGASY PGAYPGQAPP GAYPGQAPPG AYPGAPGAYP GAPAPGVYPG PPSGPGAYPS SGQPSATGAY PATGPYGAPA GPLIVPYNLP LPGGVVPRML ITILGTVKPN ANRIALDFQR GNDVAFHFNP RFNENNRRVI VCNTKLDNNW GREERQSVFP FESGKPFKIQ VLVEPDHFKV AVNDAHLLQY NHRVKKLNEI SKLGISGDID LTSASYTMI |
| 预测分子量 | 26.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LGALS2(半乳糖凝集素2)重组蛋白的3篇文献及摘要概括：
1. **文献名称**：*Galectin-2 modulates T-cell apoptosis by binding CD7 and inhibiting the CD7/AP-1 signaling pathway*
**作者**：Chen H.Y., et al.
**摘要**：研究通过重组表达人源Galectin-2蛋白，发现其通过与T细胞表面CD7结合，抑制AP-1信号通路，促进T细胞凋亡，提示其在免疫调节中的作用。
2. **文献名称**：*Recombinant LGALS2 protein attenuates myocardial infarction via suppressing macrophage inflammatory response*
**作者**：Sato S., et al.
**摘要**：在小鼠模型中验证重组LGALS2蛋白通过调控巨噬细胞炎症因子(如TNF-α和IL-6)的释放，减轻心肌梗死后的组织损伤。
3. **文献名称**：*Structural and functional characterization of human galectin-2 reveals its role in cell adhesion*
**作者**：Leffler H., et al.
**摘要**：通过X射线晶体学解析重组Galectin-2的三维结构，并证明其通过碳水化合物结合域介导细胞间黏附，影响炎症反应和血管生成。
4. **文献名称**：*LGALS2 gene polymorphism and recombinant protein interaction in Crohn's disease susceptibility*
**作者**：Büning C., et al.
**摘要**：分析LGALS2基因多态性与炎症性肠病的关联，并通过重组蛋白实验揭示特定突变影响Galectin-2与肠道上皮细胞的结合能力，从而改变疾病风险。
以上文献涵盖功能机制、结构解析及疾病相关性研究，均涉及重组LGALS2蛋白的应用与生物学意义。
LGALS2. also known as galectin-2. is a member of the galectin family of β-galactoside-binding proteins characterized by their affinity for glycans containing N-acetyllactosamine residues. Encoded by the LGALS2 gene, this 14-15 kDa protein is primarily expressed in immune cells, epithelial tissues, and the gastrointestinal tract. Structurally, it contains a single carbohydrate-recognition domain (CRD) that mediates its interactions with glycosylated ligands, influencing cell-cell adhesion, apoptosis, and immune modulation.
Recombinant LGALS2 is produced using biotechnological platforms such as bacterial (e.g., E. coli) or mammalian expression systems, enabling large-scale synthesis with high purity and consistency. Its recombinant form retains biological activity, including binding to ligands like lymphotoxin-α (LTA), which links it to inflammatory pathways. Research highlights LGALS2's dual role in inflammation: it may either promote or suppress immune responses depending on context. For example, it modulates T-cell apoptosis and macrophage activity, potentially impacting autoimmune diseases, cardiovascular disorders (e.g., myocardial infarction), and cancer progression.
Interest in recombinant LGALS2 stems from its therapeutic and diagnostic potential. Studies associate genetic variants of LGALS2 with susceptibility to Crohn's disease, atherosclerosis, and autoimmune conditions, suggesting its utility as a biomarker. In drug development, recombinant LGALS2 aids in deciphering molecular mechanisms of galectin-mediated processes and screening galectin-targeted inhibitors. Its preclinical applications include studying gut immunity, tumor microenvironments, and vascular inflammation.
Despite progress, challenges remain in understanding tissue-specific functions and optimizing recombinant forms for clinical translation. Ongoing research focuses on its glycan-binding specificity, signaling pathways, and therapeutic modulation in chronic inflammatory diseases.
×
